Lund-based medical technology company Medimi, has signed a letter of intent to acquire Norwegian company Medthings, which specializes in digital medication management. Medthings, currently launching its Mobili e-dosette device in partnership with Dignio, is expected to generate € 1.75 million (SEK 20 million) annually from this agreement. The acquisition aligns with both companies’ vision to improve medication management using innovative solutions.
Medimi’s CEO, Johan Wiesel, emphasized that the consolidation will strengthen their offering and reach a larger audience.
“Medimi and Medthings share the same vision of making medicine management better and safer for patients through the use of innovative solutions,”
Wiesel said.
The combined business is expected to generate synergies in both revenue and cost, with Medthings expected to achieve positive operating profit by 2027.
The acquisition will be carried out by issuing over € 6 million (SEK 68.9 million) worth of new Medimi shares to Medthings’ shareholders, resulting in a joint business valued at € 8.5 million (SEK 97 million). Medthings will own 71 percent of the combined company, while Medimi will hold 29 percent. Before the transaction is finalized, both companies will complete a customary due diligence process.
The acquisition is expected to be completed by December 2024, pending approval by Medimi’s extraordinary general meeting and any necessary regulatory approvals. Medimi aims to grow by at least 50 percent annually in the coming years, with the integration of Medthings playing a key role in achieving this ambitious target. Further updates regarding the acquisition will be communicated as the process unfolds.
